JP2015517565A - 疼痛の治療のためのジヌクレオシドポリリン酸 - Google Patents

疼痛の治療のためのジヌクレオシドポリリン酸 Download PDF

Info

Publication number
JP2015517565A
JP2015517565A JP2015513277A JP2015513277A JP2015517565A JP 2015517565 A JP2015517565 A JP 2015517565A JP 2015513277 A JP2015513277 A JP 2015513277A JP 2015513277 A JP2015513277 A JP 2015513277A JP 2015517565 A JP2015517565 A JP 2015517565A
Authority
JP
Japan
Prior art keywords
pain
dinucleoside polyphosphate
analog
use according
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015513277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517565A5 (enExample
Inventor
デイヴィッド ミラー、アンドリュー
デイヴィッド ミラー、アンドリュー
ロゾヴァヤ、ナターリャ
ブルナシェブ、ナイル
ジニアトゥリン、ラシッド
Original Assignee
グローバラコーン リミテッド
グローバラコーン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グローバラコーン リミテッド, グローバラコーン リミテッド filed Critical グローバラコーン リミテッド
Publication of JP2015517565A publication Critical patent/JP2015517565A/ja
Publication of JP2015517565A5 publication Critical patent/JP2015517565A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2015513277A 2012-05-25 2013-05-24 疼痛の治療のためのジヌクレオシドポリリン酸 Pending JP2015517565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201209244A GB201209244D0 (en) 2012-05-25 2012-05-25 Compositions
GB1209244.1 2012-05-25
PCT/GB2013/051377 WO2013175231A1 (en) 2012-05-25 2013-05-24 Dinuceloside polyphosphates for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2015517565A true JP2015517565A (ja) 2015-06-22
JP2015517565A5 JP2015517565A5 (enExample) 2016-07-14

Family

ID=46546668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513277A Pending JP2015517565A (ja) 2012-05-25 2013-05-24 疼痛の治療のためのジヌクレオシドポリリン酸

Country Status (8)

Country Link
US (1) US20150119352A1 (enExample)
EP (1) EP2854821A1 (enExample)
JP (1) JP2015517565A (enExample)
AU (1) AU2013264966A1 (enExample)
CA (1) CA2913313A1 (enExample)
GB (1) GB201209244D0 (enExample)
HK (1) HK1203054A1 (enExample)
WO (1) WO2013175231A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021117874A1 (ja) * 2019-12-13 2021-06-17 中外製薬株式会社 細胞外プリン受容体リガンドを検出するシステムおよび当該システムを導入した非ヒト動物
WO2026014535A1 (ja) * 2024-07-11 2026-01-15 国立大学法人旭川医科大学 子宮内膜症の予防又は治療用組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
WO2017209267A1 (ja) * 2016-06-03 2017-12-07 塩野義製薬株式会社 プリン誘導体
CN112004551A (zh) 2018-03-15 2020-11-27 丹米尔治疗有限责任公司 3”,5”-二烷氧基苯甲酰基-3’-氨基-3’-脱氧腺苷-5’-三磷酸及其药物用途
US20230032473A1 (en) * 2021-07-23 2023-02-02 Wisconsin Alumni Research Foundation Nad(h) nanoparticles and methods of use
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003238418A (ja) * 2002-02-01 2003-08-27 Inspire Pharmaceuticals Inc 痛みの治療方法
JP2008528665A (ja) * 2005-02-03 2008-07-31 イムセス リミテッド ジヌクレオチドポリリン酸誘導体の使用法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
JP2783880B2 (ja) * 1989-11-24 1998-08-06 富士レビオ株式会社 心臓病治療剤
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5681823A (en) * 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
WO2003000056A1 (en) * 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
FR2842424A1 (fr) * 2002-07-22 2004-01-23 Univ Paris 7 Denis Diderot Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003238418A (ja) * 2002-02-01 2003-08-27 Inspire Pharmaceuticals Inc 痛みの治療方法
JP2008528665A (ja) * 2005-02-03 2008-07-31 イムセス リミテッド ジヌクレオチドポリリン酸誘導体の使用法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N VOITENKO: "ANTINOCICEPTIVE EFFECTS OF NON-HYDROLIZABLE DIADENOSINE POLYPHOSPHATE ANALOGUES", INTERNET CITATION [ONLINE], JPN5015006712, 1 January 2010 (2010-01-01), pages 60, ISSN: 0003523953 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021117874A1 (ja) * 2019-12-13 2021-06-17 中外製薬株式会社 細胞外プリン受容体リガンドを検出するシステムおよび当該システムを導入した非ヒト動物
JPWO2021117874A1 (enExample) * 2019-12-13 2021-06-17
CN114787362A (zh) * 2019-12-13 2022-07-22 中外制药株式会社 检测细胞外嘌呤受体配体的系统和导入该系统的非人动物
JP7765290B2 (ja) 2019-12-13 2025-11-06 中外製薬株式会社 細胞外プリン受容体リガンドを検出するシステムおよび当該システムを導入した非ヒト動物
WO2026014535A1 (ja) * 2024-07-11 2026-01-15 国立大学法人旭川医科大学 子宮内膜症の予防又は治療用組成物

Also Published As

Publication number Publication date
EP2854821A1 (en) 2015-04-08
AU2013264966A1 (en) 2015-01-22
CA2913313A1 (en) 2013-11-28
US20150119352A1 (en) 2015-04-30
WO2013175231A1 (en) 2013-11-28
GB201209244D0 (en) 2012-07-04
HK1203054A1 (en) 2015-10-16

Similar Documents

Publication Publication Date Title
CN108348492B (zh) 使用谷氨酰胺类似物的用于癌症和免疫疗法的方法
Zhang et al. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility.
Cui et al. Mdivi-1 protects against ischemic brain injury via elevating extracellular adenosine in a cAMP/CREB-CD39-dependent manner
US20150119352A1 (en) Dinuceloside polyphosphates for the treatment of pain
WO2009151569A2 (en) Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2009011897A1 (en) Combinations for the treatment of b-cell proliferative disorders
EP1603577B1 (en) Compounds for the treatment of pain
KR20240105341A (ko) Htcp 억제제에 의한 죽상동맥경화증, 원발성 담즙성 간경화증 및 nrlp3 인플라마좀-관련 질환의 치료법
US8618074B2 (en) GPCR enhanced neuroprotection to treat brain injury
KR20050115895A (ko) 치료법에 있어서의 아데노신 수용체 작용제의 용도
US11291681B2 (en) Method for treating fibrotic liver tissue using Cl-IB-MECA
TW201808301A (zh) Acvr1介導之疾病之治療
Krivoshein et al. Sex difference in TRPM3 channel functioning in nociceptive and vascular systems: an emerging target for migraine therapy in females?
WO2016134257A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
WO2014124523A1 (en) A method of treating obesity
WO2008031831A2 (en) Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
Class et al. Patent application title: DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN Inventors: Andrew David Miller (Chiswick, GB) Natalya Lozovaya (Marseille, FR) Nail Burnashev (Marseille, FR) Rashid Giniatullin (Kuopio, FI) Assignees: GlobalAcornLtd.
EP3989979B1 (fr) Inhibiteurs de l'entree capacitive du calcium
EP1709968A1 (en) P2x receptor inhibitor
US20200306285A1 (en) Methods for treating cancer using purine analogs by depleting intracellular atp
JP2017502930A (ja) 組成物
Mackins Modulation of norepinephrine release by endogenous mediators in myocardial ischemia
HK1261991A1 (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
HK1261991B (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
JP2018168069A (ja) 新規鎮痛剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171208